Literature DB >> 21848464

Development of antiretroviral drug resistance.

Mark A Wainberg1, Gerasimos J Zaharatos, Bluma G Brenner.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21848464     DOI： 10.1056/NEJMra1004180

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  82 in total

1.  Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.

Authors:  M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

Review 2.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

3.  High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.

Authors:  Henry Sunpath; Baohua Wu; Michelle Gordon; Jane Hampton; Brent Johnson; Mahomed-Yunus S Moosa; Claudia Ordonez; Daniel R Kuritzkes; Vincent C Marconi
Journal:  AIDS       Date:  2012-08-24       Impact factor: 4.177

Review 4.  Systematic review of HIV drug resistance in Southeast Asia.

Authors:  Andrew B Trotter; Steven Y Hong; Padmini Srikantiah; Iyanthi Abeyewickreme; Silvia Bertagnolio; Michael R Jordan
Journal:  AIDS Rev       Date:  2013 Jul-Sep       Impact factor: 2.500

5.  Antiretroviral Therapy Interruption Among HIV Postive People Who Use Drugs in a Setting with a Community-Wide HIV Treatment-as-Prevention Initiative.

Authors:  Ryan McNeil; Thomas Kerr; Bill Coleman; Lisa Maher; M J Milloy; Will Small
Journal:  AIDS Behav       Date:  2017-02

6.  Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.

Authors:  Melissa Wares; Said Hassounah; Thibault Mesplède; Paul A Sandstrom; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

7.  Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.

Authors:  Diane N Singhroy; Mark A Wainberg; Thibault Mesplède
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

8.  Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor.

Authors:  Ying-Shan Han; Wei-Lie Xiao; Hongtao Xu; Victor G Kramer; Yudong Quan; Thibault Mesplède; Maureen Oliveira; Susan P Colby-Germinario; Han-Dong Sun; Mark A Wainberg
Journal:  Antivir Chem Chemother       Date:  2015-02

9.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

10.  Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.

Authors:  D Rajotte; S Tremblay; A Pelletier; P Salois; L Bourgon; R Coulombe; S Mason; L Lamorte; C F Sturino; R Bethell
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.